dm+d
Unassigned
New Medicines
ZimuraAge-related macular degeneration (AMD); geographic atrophy (advanced dry-type AMD)
Information
Zimura
New molecular entity
Iveric Bio
Iveric Bio
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
Complement C5 inhibitor; an oligonucleotide aptamer that inhibits a central component of the complement cascade
Geographic atrophy is the most common form of AMD overall, but comprises only about 40% of late AMD; estimated prevalence of late AMD in the UK is 4.8% of those over 65 years of age and 12.2% of those aged 80 years or more [3].
Age-related macular degeneration (AMD); geographic atrophy (advanced dry-type AMD)
Intravitreal